

Uroveda - Institute of Urogenital Diseases

2439 Kuser Road • Hamilton, NJ 08690-3303 (609) 570-1000 • Fax (609) 245-7665



Toll Free (877) 269-0090 www.mdlab.com A MEMBER OF GENESIS BIOTECHNOLOGY GROUP **Urology Test Requisition Form** Ordering Physician/Laboratory **Patient Information (Please Print)** Name (Last, First) (Required) quired: Include the ordering physician's first & last name, NPI, practice name, complete address, phone number and fax number.) In Care of Patient Address: Date of Birth (Required) Patient ID#: ssigned Sex at Birth (Reg ☐ Female ☐ Male Phone Number: Ethnicity: Hispanic or Latino
Not Hispanic or Latino
Unknown Race: ☐ Alaska Native or American Indian ☐ Asian ☐ Black or African American | Multiracial | Native Hawaiian or other Pacific Islander | Other race | White | Does not wish to disclose | Not provided Gender Identity: ☐ Male ☐ Female ☐ Gender nonconforming ☐ Tra
☐ Transgender female-to-male ☐ Does not wish to disclose ☐ Not provided ☐ Transgender male-to-female Sexual Orientation:
Bisexual Straight Gay or Lesbian Something else Does not wish to disclose Physician to receive additional result report: Physician's Signature: Date Billing Information (Please include a copy of the front & back of card.) Billing Type: Patient Insurance Client Relation (Required): Self Spouse Dependent Insured's Name (if not patient): Prostate-related Clinical Information Insured's SS#: Insured's DOB: Patient History (Or Biopsy History: ☐ No prior biopsy
☐ Yes, negative ☐ Confirmed PSA ≥ 3.0 ng/ml Primary Insurance Carrier: Medicare, Medicaid or Policy ID#: ☐ Confirmed persistent significant rise in PSA ☐ Yes, positive (4Kscore test will not be ☐ Confirmed very suspicious DRE Claims Address: ☐ Other (please specify): d with a positive biopsy result) **DRE Results:** Employer/Group Name: Group#: □ Nodule □ No Nodule □ Not performed. Prostate Information ICD10 codes (required): ☐ T2c ☐ T Last % Free PSA Clinical Stage: □ T2b □ T2a ___ng/mL on _/_/_ Last % Free

__stable Previous 4Kscore:
__ Negative __ Atypical __ Positive PSA Trend: Increasing Bladder Biopsy Information Previous Biopsy:

None Digital Rectal Éxam: ☐ Suspicious ☐ Non-suspicious Collected (Req.) Collector Signature No. vials collected ☐ PIRAD Level MpMRI: ☐ Other (please specify): ☐ Chemotherapy ☐ Prostatectomy ☐ Radiation ☐ Cryotherapy Treatment: Bladder-related Clinical Information (Necessary for accurate test interpretation) ☐ TURP ☐ Active Surveillance □ Hormones ☐ None Date of Diagnosis: □ High-grade urothelial carcinoma □ Carcinoma in-situ
□ Papilloma □ Other (please specify): **Prostate Biopsy Information** Small-cell carcinoma Adenocarcinoma Prostate Cancer Please indicate individual specimens(s) below Low-grade urothelial carcinoma Hematuria □ Dysuria ☐ Resection ☐ BCG ☐ Chemotherapy ☐ Other (please specify) Treatment: Time Collected ☐ Radiation **Urologic Specimen Information** ☐ Voided Urine ☐ Catheterization (Urine) Collector Signature: ☐ Bladder Washing ☐ Ileal Conduit ☐ Brushing **Urine Test Selection** No. vials collected CYTOLOGY - Urine Specimens Only Required: Fresh Specimen Fixed 1603 ☐ Urine Cytology 1604 Comprehensive Urine Pathology (Urine Cytology and UroVysion®) With Interpretation: ☐ Other (please specify): ☐ Prostate Biopsy - # of jars: Sexually Transmitted Infections - UroSwab® ☐ Bladder Biopsy - # of jars: Common ICD10 codes (required):

Z20.2 Contact with and (suspected) exposure to infections with a predominantly sexual mode of transmission Definition of the contact with a predominantly sexual mode of transmission Other: 5620-0 □ VAS Deferens/X2 Confirmation of Informed Consent and Medical Necessity for Pharmacogenomic Genetic Testing R36.9 Urethral discharge, unspecified 191
Sexually Transmitted Disease (STD) Screen by Real-Time PCR Includes-My signature below acknowledges the patient has been informed about the purpose, limitation and possible risks of genetic testing. The patient has been given the opportunity to ask questions about this consent and seek outside genetic counseling. 121 Leukorrhea Panel (N. gonorrhoeae*, C. trachomatis**, T. vaginalis)
105 Chlamydia trachomatis (**Reflex to antibiotic resistance by Molecular Analysis) If the genetic testing is covered by the patient's health plan and the out-of-pocket expense is less than \$150.00, testing will proceed without further delay or additional contact. The patient's signed informed consent is being provided with this requisition. I confirm that this testing is medically necessary for the specified patient and that these results will be used in the medical management and treatment decisions for this patient. 167
Neisseria gonorrhoeae (*Reflex to antibiotic resistance by Molecular Analysis) 111

Trichomonas vaginalis (Reflex to metronidazole resistance) 129 Mycoplasma genitalium (Reflex to azithromycin & fluoroquinolone resistance by Pyrosequencing) Medical Professional Signature (Req.): 130 ☐ Mycoplasma hominis 320 Ureaplasma urealyticum (†Reflex to fluoroquinolone resistance by Pyrosequencing) Pharmacogenomic Genetic Testing Specimen Information Specimen Source: Saliva ☐ Whole Blood Urinary Tract Infections - UroSwab® Common ICD10 codes (required):
N39.0 □ Urinary tract infection, site not specified Hereditary Genetics Testing - Saliva or Whole Blood R30.1

Vesical tenesmus *Informed Consent form must accompany specimen R30.0 Dysuria ☐ Other: Hereditary Prostate Cancer Panel (18 genes) by Gene Sequencing and Deletion/Duplication Analysis (ATM, BRCA1, BRCA2, BRIP1, CHEK2, EPCAM, FANCA, HOXB13, MITF, MLH1, MSH2, MSH6, NBN, PALB2, PMS2, RAD51C, RAD51D, TP53) Hereditary Renal Cancer Panel (19 genes) by Gene Sequencing and Deletion/Duplication Analysis (BAP1, EPCAM, FH, FLCN, MET, MITF, MLH1, MSH2, MSH6, PALB2, PMS2, PTEN, SDHB, SDHC, SDHD, TP53, TSC1, TSC2, VHL) Lynch Syndrome Gene Panel: 5 Genes (EPCAM*, MLH1, MSH2, MSH6, PMS2) by Gene Sequencing with Deletion/Duplication Analysis (*Deletion/Duplication Analysis of Exon8-9 only) ting includes sequencing for all genes except EPCAM (del/dup only) and MITF 176 Urinary Pathogens Antibiotic Resistance* Includes -☐ Escherichia coli-AC, C, TS, N, CP, F 727 ☐ Klebsiella oxytoca-AC, C, TS, N, CP, F ☐ Enterococcus faecalis-A, N, CP, F, D, L 146 ☐ Proteus mirabilis-AC, C, TS, N, CP, F ☐ Enterococcus faecium-A, N, CP, F, D, L 174 ☐ Pseudomonas aeruginosa-CF, PT, I, A, G ☐ Klebsiella pneumoniae-AC, C, TS, N, CP, F , 153, 154, 728, 727, 146 or 174 Req. When panel is ordered and individual tests are not selected, all 7 will be ormed & billed) 141 ☐ Escherichia coli-AC, C, TS, N, CP, F 1279 🗆 551 ☐ Candida albicans 559 ☐ Candida glabrata Testing includes sequencing for all genes except EPCAM (del/dup only) and MITF (evaluation of C.952g>A only). Enterobacter cloacae 730 🗆 127 🗆 Group B Streptococcus (GBS) Pharmacogenetics Testing - Saliva or Whole Blood 731 ☐ Klebsiella aerogenes 362 Prevotella species Group 1 (*P. bivia, P. disiens, P. 1intermedia, P. melaninogenica*)
363 Prevotella species Group 2 (*P. corporis, P. albensis*) Informed Consent form must accompany specimen

Bladder Cancer-Cisplatin, Erdafitinib (ABCB1, CYP2C9, CYP3A4, MTHFR, TPMT) 3708 □ Prostate Cancer-Abiraterone, Apalutamide, Cabazitaxel, Doctaxel, Enzalutamide

3709 □ Flutamide, Goserelin, Leuprolide, Nilutamide, Prednisone/Prednisolone (ABCB1, CYP1A2, CYP2C19, CYP2D6, CYP3A4, CYP3A5, CYP2C8, SLCO1B1)

3707
Bladder Incontinence-Darifenacin, Fesoterodine, Mirabegron, Tamsulosin,

Tolterodine (CYP2D6, CYP3A4, CYP3A5)

151 ☐ Staphylococcus saprophyticus 178 ☐ Ureaplasma parvum (Reflex to fluoroquinolone resistance by Pyrosequencing) Refer to the back for antibiotic abbreviation key.

IH0233 Upd.: 12.2023

734
Proteus vulgaris

Providencia species (P. stuartii, P. rettgeri)

Antibiotic Abbreviations Key

A = aztreonam AC= amoxicillin-clavulanic acid, AP = ampicillin, AZ = azithromycin, CC = ceftriaxone/cefixime, C = cephalothin (cephalexin), CF = cefepime, CP = ciprofloxacin, CL = clindamycin, D = doxycycline, F = fosfomycin, FL = fluoroquinolone G = gentamicin, I = imipenum, L = linezolid, M = metronidazole N = nitrofurantoin, PT = piperacillin-tazobactam, TS = trimethoprim-sulfamethoxazole.

Medical Necessity Guidelines:

Physicians must only order tests that they have determined are medically necessary for the diagnosis and treatment of a patient. MDL offers individual tests, as well as a limited number of customized panels. MDL provides practitioners with the flexibility to choose appropriate individual tests for each specimen to assure that the convenience of ordering panels does not impede them from ordering tests/panels that are medically necessary. All tests listed in panels may be ordered individually using this test requisition form. If you choose to order a panel, please make certain that each and every test is medically necessary. If you check off a panel as your choice, MDL understands that the physician has determined that all of the component tests are medically necessary, and will perform, report and bill for all such component tests.

** This test can only be performed when the test in parenthesis is positive. All tests performed will be billed. Test by Real-Time PCR unless otherwise specified.

UroSwab® is registered in the USPTO.

Specimen C	ollection Platform	TAT*	Stability	Test Additions [*]	
Biopsies	diction and	3 - 5 days	7 days	30 days to add tests	Collect specimen and insert into the formalin vial. The following times must documented on the test requisition form: Time of specimen removal from patient Time when specimen was placed into formalin
UroSwab®	UroSwab 1	24 - 72 hours	4 days	14 days to add tests	 Have patient collect a urine specimen in a collection cu Dip the sponge swab into collection cup to absorb the urine. Tightly re-secure the cap on the vial.
Urine (for UroVysion® testing)	Milde Barrier	7 days	24 hours	N/A	 Collect a second morning, clean-catch voided urine. Minimum volume of 33 mL required, 60 mL desired Store in refrigerator (4°C) until ready for transport Pre-freeze cold packs flat to ensure fit in transport box Do not collect/ship urine specimens on a Saturday
Whole Blood	Yellow Top Tube (ACD Solution A)	3-5 days	48 hours	30 days to add tests	In accordance with the standard operating procedure of your facility, collect blood in two yellow top (ACD solution A) tubes. Allow the tubes to fill properly to ensure the proper blood to anticoagulant ratio. Invert gently several times to mix and prevent clot formation. Do not shake the tubes. Do not centrifuge.
Saliva	(fin)	5 - 10 days	48 hours	30 days to add tests	Vigorously rinse mouth with clean water 5 minutes prior to specimen collection (30 minutes prior is ideal). After rinsing, do not brush teeth, use mouthwash, eat, drink, chew gum or smoke prior to sample collection. Begin collecting your sample by allowing saliva to pool in your mouth. Then spit into the wide funnel of the tube allowing saliva to collect in the upper chamber of the tube. Fill the tube until the amount of saliva (not bubbles) reaches the fill line as shown. Once filled, unscrew the funnel allowing the saliva to flow into the lower chamber of the tube containing the stabilizing solution. Discard the funnel. Use the blue cap to close the tube tightly. Shake the capped tube for 5 seconds.

^{*} Up to 72 hours with reflex/antiobiotic resistance testing

Specimen Packaging:

- 1. Label every vial with a minimum of 2 patient identifiers including the patient's name and date of birth. Be sure the name on the vial is written exactly the same way as on the test requisition form.
- 2. Place the vial into the Styrofoam/Cardboard container. You can fit up to 3 vials in one container.
- 3. Place the Styrofoam/Cardboard container into the central pocket of a biohazard bag containing absorbent material.
- 4. Place a completed test requisition form for each vial in the front pocket of the biohazard bag.
- 5. Place the biohazard bag into the prepaid Lab pack Envelope that has a preaddressed airbill attached. One envelope will accommodate 6-7 containers. Package as many containers in one Labpack as possible.
- 6. Be sure to seal the Lab pack by removing the plastic from the top of the adhesive.

Specimen Pick-up:

- If you have a specimen pick-up for a local courier in the NJ, PA, DE, D.C., MD, VA, KS, MO or Phoenix, AZ area, please call (877) 205-0005 no later than 2 hours prior to the closing of your facility.
- If you have a specimen pick-up, please call your sales representative or MDL customer service at 877.269.0090 no later than 2 hours prior to the closing of your facility.

Helpful Hints Checklist

Please review these helpful hints to reduce specimen discrepancies and enhance turnaround time.

Verify Patient Name - did you:

- ✓ attach the correct demographics sheet?
- ✓ write the patient's name on the requisition form?

Patient Name Matches on Vial & Requisition Form-did you:

- ✓ make sure names on vial and requisition form match?
- ✓ list the patients married or maiden name?
- ✓ list a nickname by mistake?

Verify Date of Collection- did you:

- ✓ write the correct year?
- ✓ write the correct month?
- ✓ list the date of birth instead?

Verify Tests- did you:

- ✓ clearly mark each box?
- ✓ order tests appropriate for the specimen type?

No Tests Ordered- did you:

✓ mark the boxes for the tests/panels ordered?

Supply Orders:

Easily place supply orders online by visiting our website:



http://www.mdlab.com/physicians/supplies/#

Supply orders may also be placed by contacting our Client Services department toll free 877.269.0090 or by fax 609.570.1050. Supply requests are processed and shipped on a daily basis. Please allow 3 to 5 business days for delivery, depending upon your location.

MDL Contact Information	TOLL	FAX
GBS Hotline 24 hours - 7 days a week Group B Strep & HSV results only	877.MDL.GBS7 877.635.4277	
Quality Control Department For Technical Assistance	877.269.0090	609.245.7665
Client Services General Questions, Results	877.269.0090	609.570.1050
Client Services Billing Questions	877.333.9233	609.245.7683

^{*}Pending QC review for sufficient specimen volume